secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2022-09-01T23:59:59+00:00
Accession:  0001193125-22-236658
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase appoints Gisele Dion to Board, replacing retiring Elizabeth O'Farrell
--------------------------------------------------------------------------------

- Elizabeth O'Farrell retired from the Board effective Sep 1, 2022; departure not due to any disagreement.
- Gisele Dion appointed as Class III director effective Sep 1, 2022.
- Dion receives $65k annual cash and a 60,000-share option grant (50% vest each of first two anniversaries).
- Dion previously SVP & CAO at Takeda, CAO at Shire, and board member at Cytek Biosciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312522236658/0001193125-22-236658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312522236658/d283919d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-236658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer